Click here to read the article
How healthcare and biotech investment trusts can revive portfolios
Healthcare and biotechnology trusts have not been immune to the stock market ravages of the coronavirus pandemic, but have fared better than others. Looking beyond the crisis, the sector will be propelled forwards by strong tailwinds, argues David Prosser.
Published on 5th May 2020